The EU Pharma Package and Critical Medicines Act: What Global Companies Need to Know in 2026

After a decade-long revision process, the European Union's new General Pharmaceutical Legislation (widely known as the "Pharma Package") has reached its final stages. With compromise texts published in March 2026 and formal adoption expected by the summer, the new Pharmaceutical Directive and Regulation will officially replace the framework that has governed the bloc since 2004.

This comprehensive reform is designed to address patient access disparities, unmet medical needs, and the severe supply chain vulnerabilities exposed during the COVID-19 pandemic. Paired with the newly agreed Critical Medicines Act (CMA), this legislative overhaul introduces a strict new paradigm for global pharmaceutical and biotechnology companies operating in Europe. Full application is anticipated for late 2028, but preparations must begin now.

Key Regulatory Changes Under the EU Pharma Package

1. Reduced and Modulated Regulatory Protections

Historically, the EU offered a reliable "8+2+1" framework: eight years of regulatory data protection, two years of market protection, and a possible one-year extension for a new indication offering significant clinical benefit.

The new framework shifts to an "8+1(+1)+1" model. Baseline regulatory market protection is reduced from two years to one. However, companies can "earn back" additional protection through a modulated extension mechanism if:

• The product addresses an unmet medical need (targeting a life-threatening or severely debilitating disease with no existing authorized treatment, or offering a clinically meaningful improvement).
• The product contains a new active substance and meets specific conditions related to comparator trials and EU-first filing.

A refusal by the European Medicines Agency (EMA) to grant "unmet medical need" status will now have cascading negative effects, not only on market protection but also on subsequent national pricing and reimbursement negotiations.

2. Expanded Bolar Exemption

The Bolar exemption, which permits generic and biosimilar developers to conduct pre-expiry studies without infringing patents, has been materially broadened. It now explicitly covers activities required for obtaining pricing and reimbursement approvals, conducting health technology assessments (HTA), and submitting applications for procurement tenders.

3. Stringent Launch and Supply Obligations

In a shift from the Commission's original proposal-which would have penalized companies that did not launch in all 27 Member States-the final text adopts a targeted "best efforts" regime. Member States can now formally request a marketing authorization holder to place a protected product on their market and ensure continuous supply. This requires submitting valid pricing applications and establishing rollout plans.

Failure to make the product available within three years of such a request can result in the loss of regulatory market protection in that Member State, allowing generic competitors to validate applications earlier.

4. Changes to Orphan Medicinal Products

Orphan market exclusivity (OME) has also been restructured. The new framework provides nine years of OME for standard orphan products, while maintaining 11 years for "breakthrough" orphan products (those treating conditions with no authorized alternatives and delivering significant reductions in morbidity). The previous two-year extension for completing pediatric investigations has been replaced by a six-month supplementary protection certificate (SPC) extension.

5. Transferable Exclusivity Vouchers for Antimicrobials

To combat antimicrobial resistance (AMR), the regulation creates a highly lucrative incentive: a transferable voucher granting an additional 12 months of regulatory data protection for a "priority antimicrobial." Capped at five vouchers across the EU, these can be used by the developer or sold/transferred to another company to extend the exclusivity of an entirely different, highly profitable product.

The EU Critical Medicines Act: A Companion Regime

Operating alongside the Pharma Package is the Critical Medicines Act (CMA), which reached a provisional political agreement on May 12, 2026. While the Pharma Package focuses on regulatory pathways, the CMA acts as an industrial-policy layer targeting supply chain resilience.

Key features of the CMA include:

• Mandatory Procurement Diversification: Public procurement will no longer default to the "lowest price." Authorities must reward supply chain resilience and EU-based manufacturing.
• Strategic Projects: Criteria are established for EU-based strategic manufacturing projects. Funded companies will receive accelerated permitting and financial support but must prioritize EU supply.
• Joint Procurement: The Commission is enabled to initiate joint procurement on behalf of five or more Member States to increase bargaining power.
• Solidarity and Transparency: Strict transparency rules are implemented to prevent conflicting contingency stock requests among Member States.

What Global Companies Should Do Next

The EU's pharmaceutical landscape is being aggressively reshaped. Innovator protections are shorter by default, supply obligations are strictly enforceable, generic pathways have broadened, and a new industrial framework actively favors European-based manufacturing.

While the rules will apply 24 months after entry into force (late 2028), companies must act immediately. Strategic imperatives include:

1. Evaluating Pipeline Impacts: Assess how the new "unmet medical need" definitions and comparator trial requirements will affect upcoming filings.
2. Reviewing Global Filing Strategies: Consider the implications of the new modulation criteria, particularly the EU-first filing incentives.
3. Supply Chain Preparedness: Monitor CMA implementation closely, ensuring your manufacturing footprints align with the new procurement diversification and stockpiling obligations.